Associated Papers
Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.
Aigner C et al.
Kidney Medicine, 2026
Evaluation of the impact of two C5 genetic variants on C5-eculizumab complex stability at the molecular level.
Peixoto VP et al.
Journal of Biomolecular Structure & Dynamics, 2025
The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms.
Bouwman HB et al.
Drug Discovery Today, 2024
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Tang GQ et al.
Frontiers in Immunology, 2023
An inhibitor of complement C5 provides structural insights into activation.
Reichhardt MP et al.
Proceedings of the National Academy of Sciences of the United States of America, 2020
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.
Wijnsma KL et al.
Clinical Pharmacokinetics, 2019
Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
Alobaidi S et al.
Cen Case Reports, 2019
Stratification of responders towards eculizumab using a structural epitope mapping strategy.
Volk AL et al.
Scientific Reports, 2016
Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria.
Du Y et al.
International Journal of Laboratory Hematology, 2016
Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Wong EK et al.
Translational Research : the Journal of Laboratory and Clinical Medicine, 2015
Genetic variants in C5 and poor response to eculizumab.
Nishimura J et al.
The New England Journal of Medicine, 2014
Select a paper to view details